A critical review of management of allogeneic transplant‐eligible adults with Ph+ acute lymphoblastic leukaemia

Abstract

SummaryAcute lymphoblastic leukaemia (ALL) in 20%–30% of adult patients contains the Philadelphia (Ph+) chromosome. Historically, Ph+ ALL denoted a markedly inferior outcome and long‐term survival in the absence of an allograft was uncommon. However, the advent of targeted therapy directed against the BCR::ABL1 fusion protein with various tyrosine kinase inhibitors (TKIs) has markedly improved the prognosis, resulting in a number of treatment controversies in allograft‐eligible patients. Which is the best TKI to use in induction? What is the clinical relevance of the subdivision of Ph+ ALL into multilineage vs lymphoid types? Do all patients in first morphological complete remission (CR1) after induction and consolidation with chemotherapy/TKI require an allograft? If not, what risk factors predict a poor outcome without an allograft? Can chemotherapy‐free approaches, such as blinatumomab in conjunction with more potent TKIs, obviate the need for an allograft in high‐risk patients? What is the best strategy to deal with persistent or emerging minimal residual disease both pre‐ and post‐transplant? Is maintenance TKI indicated in all patients post allograft? Can salvage therapy and a subsequent allograft cure patients who relapse after not being transplanted in CR1? This manuscript reviews the latest data influencing contemporary management and discusses these controversies.